Translational research and efficacy of biologics in Crohn's disease: a cautionary tale

References

• Abraham C, Cho JH. Inflammatory bowel disease: mechanisms of disease. N Engl J Med 2009;361(21):2066-78
   PubMed Web of Science ®Google Scholar
• Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009;31(3):401-11
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):644-59
   PubMed Web of Science ®Google Scholar
• Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998;4(4):328-9
   PubMedGoogle Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61(6):918-32
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136(4):1182-97
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77(4 Pt 2):843-6
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121(2):268-74
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126(4):989-96
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122(2):512-30
   PubMed Web of Science ®Google Scholar
• Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013;37(8):786-94
   PubMed Web of Science ®Google Scholar
• Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep 2010;12(6):471-8
   PubMedGoogle Scholar
• Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 2012;18(2):368-71
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474(7351):298-306
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372(9632):67-81
   PubMed Web of Science ®Google Scholar
• Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011;17(5):547-56
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-41
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367(16):1519-28
   PubMed Web of Science ®Google Scholar
• Mannon P, Fuss I, Mayer L, et al. Anti–interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351(20):2069-79
   PubMed Web of Science ®Google Scholar
• Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16(7):1209-18
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barisch C, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's Disease. Inflamm Bowel Dis 2006;12(7):558-65
   PubMed Web of Science ®Google Scholar
• Su C, Lichtenstein G, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126(5):1257-69
   PubMed Web of Science ®Google Scholar
• Herrlinger K, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7(8):636-43
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut 2012;61(12):1693-700
   PubMed Web of Science ®Google Scholar
• Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13(8):1016-23
   PubMed Web of Science ®Google Scholar
• Sagiv-Friedgut K, Karban A, Weiss B, et al. Early-onset Crohn's disease is associated with male sex and a polymorphism in the IL-6 promoter. J Pediatr Gastroenterol Nutr 2010;50(1):22-6
   PubMed Web of Science ®Google Scholar
• Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1138-44
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1131-7
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16(2):233-42
   PubMed Web of Science ®Google Scholar
• Semerano L, Assier E, Boissier MC. Anti-cytokine vaccination: a new biotherapy of autoimmunity? Autoimmun Rev 2012;11(11):785-6
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108(1):40-7
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Rogler G, Van der Bijl A, et al. Safety, immunogenicity and clinical phase i-ii results of TNF-kinoid immunotherapeutic in Crohn's disease patients. Gastroenterology 2011;140(5 Suppl 1):123
   Google Scholar
• NEOVACS 2012. Phase II Clinical Trial of TNF-alpha Kinoid in Crohn's Disease. Online interim report. Available from: http://www.neovacs.fr/files/news/e2c1c87c4e58b9adbc47b7dc9f4978c5.pdf [Accessed on 3 October 2013]
   Google Scholar
• Lee JC, Laydon J, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-46
   PubMed Web of Science ®Google Scholar
• English JM, Cobb M. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002;23(1):40-5
   PubMed Web of Science ®Google Scholar
• Lee J, Kassis S, Griswold D, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47(2-3):185-201
   PubMed Web of Science ®Google Scholar
• Wadsworth SA, Cavender D, Beers SA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291(2):680-7
   PubMed Web of Science ®Google Scholar
• Hommes DW, Van den Blink B, Bartelsman J, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122(1):7-14
   PubMed Web of Science ®Google Scholar
• Dotan I, Rachmilewitz D, Schreiber S, et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 2010;59(6):760-6
   PubMed Web of Science ®Google Scholar
• Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(3):325-34
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Park H, Pesu M, et al. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 2005;17(7):305-11
   PubMedGoogle Scholar
• Kremer JM, Bloom B, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60(7):1895-905
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson M, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186(7):4234-43
   PubMed Web of Science ®Google Scholar
• Sandborn W, Ghosh S, Panes J, et al. Phase 2 study of CP-690,550, an oral Janus Kinase Inhibitor in active Crohn's Disease. Gastroenterology 2011;140(5):S1-124
   Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616-24
   PubMed Web of Science ®Google Scholar
• Izcue A, Coombes J, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009;27:313-38
   PubMed Web of Science ®Google Scholar
• Qiu BS, Pfeiffer CJ, Keith JC Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996;41(8):1625-30
   PubMed Web of Science ®Google Scholar
• Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab invest 1998;78(12):1503-12
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10(3):170-81
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75(2):263-74
   PubMed Web of Science ®Google Scholar
• Schreiber S, Heinig T, Theile HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108(5):1434-44
   PubMed Web of Science ®Google Scholar
• van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113(2):383-9
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119(6):1473-82
   PubMed Web of Science ®Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000;119(6):1461-72
   PubMed Web of Science ®Google Scholar
• Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011;3(11):1341-52
   PubMed Web of Science ®Google Scholar
• Cottone M, Orlando A, Renna S. Investigational agents for Crohn's disease. Expert Opin Investig Drugs 2010;19(10):1147-59
   PubMed Web of Science ®Google Scholar
• Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999;117(1):58-64
   PubMed Web of Science ®Google Scholar
• Sands B, Winston B, Salzberga A, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002;16(3):399-406
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101(4):793-7
   PubMed Web of Science ®Google Scholar
• Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012;20(1):1-18
   PubMedGoogle Scholar
• Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011;5:185-210
   PubMed Web of Science ®Google Scholar
• Keshav S, Vaňásek T, Niv Y, et al. Prospective Randomized Oral-Therapy Evaluation in Crohn's Disease Trial-1 PROTECT-1 Study Group. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013;8(3):e60094
   PubMed Web of Science ®Google Scholar
• Hamamoto N, Maemura K, Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 1999;117(3):462-8
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120(6):1339-46
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114(6):1133-42
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey W, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51(1):30-6
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5(2):215-20
   PubMed Web of Science ®Google Scholar
• Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active controlled trial. Aliment Pharmacol Ther 2006;23(10):1403-13
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012;18(12):2203-8
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013;19(3):621-6
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106(4):674-84
   PubMed Web of Science ®Google Scholar
• Mayer L, Kaser A, Blumberg RS. Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology 2012;143(1):13-17
   PubMed Web of Science ®Google Scholar
• Marlow GJ, van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol 2013;19(25):3931-41
   PubMed Web of Science ®Google Scholar
• Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 2010;39(3):543-57
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor expressing cells. Arthritis Rheum 2008;58(5):1248-57
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-8
   PubMed Web of Science ®Google Scholar
• Carbo A, Hontecillas R, Kronsteiner B, et al. Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput Biol 2013;9(4):e1003027
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2013;7(6):549-58
   PubMed Web of Science ®Google Scholar
• Dassopoulos T, Sninsky CA. Optimizing immunomodulators and anti-TNF agents in the therapy of Crohn's disease. Gastroenterol Clin North Am 2012;41(2):393-409
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2011;17(6):1428-35
   PubMed Web of Science ®Google Scholar
• Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010;8(7):591-9
   PubMed Web of Science ®Google Scholar